Europe
InflaRx reported additional in-depth analysis of the completed double blind, placebo controlled part of the ongoing international SHINE Phase IIb study to supplement InflaRx’s top line disclosure of results reported on June 5, 2019.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Pharma and biotech companies from across the globe expand their leadership teams and boards.
Novartis saw a strong boost in sales during the second quarter, driven by Cosentyx and Entresto, as well as a 9% growth in oncology sales, the company announced this morning.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Bridge Biotherapeutics licensed out its BB-877 to Boehringer Ingelheim for a total deal of about $1.75 billion. This is the second large deal for fibrotic diseases Boehringer Ingelheim inked since the beginning of the month.
In May, the company sold off assets worth $5.7 billion and now, the company is looking to sell more.
The companies will develop therapies that target the complement cascade, a group of proteins known to play a role in autoimmune diseases.
Genmab A/S, located in Copenhagen, Denmark, raised $506 million with its initial public offering (IPO). The company trades on the Nasdaq under the ticker symbol GMAB.
Adocia, the clinical-stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announces its financial results for the first six months ended June 30, 2019.
PRESS RELEASES